Multi-organ Responses to CHronic Physical Activity and INactivity

Metabolic Syndrome Clinical Trial

— CHAIN  

Official title:

Concurrent Multi-organ Responses to CHronic Physical Activity and INactivity Intervention, to Increase Research Discovery in Human Health and Wellbeing

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06377254
• Other study ID #: BB/X015173/1
• Status: Recruiting
• Phase: N/A
• Start date: March 12, 2024
• Est. completion date: October 31, 2028

Study information

• Verified date: April 2024
• Source: University of Nottingham
• Contact: Paul Greenhaff (PI), PhD
• Phone: +44 (0) 1158230133
• Email: paul.greenhaff[@]nottingham.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Life expectancy has been increasing for the last 150 years, but the maintenance of health has not kept pace with increased lifespan, and on average, UK adults spend the last decade of life in poor-health, with major consequences for society and the individual. Persistent physical inactivity is thought to be a key contributing factor to the risk of poor health and functional decline occurring in middle-aged and older adults. It is therefore concerning that most middle-aged adults spend >8hrs/day being sedentary, with average step count of 3000-4000 steps/day. To be able to holistically assess the effectiveness of future strategies to address age-related decline in health, and devise public health messages to help individuals reach older age in better health, it is essential that the complex physiological effects that activity and inactivity have across biological systems are characterised. The goal of this intervention study is to compare the impact of physical activity and inactivity on body functioning. Twenty moderately active participants will decrease their physical activity for six months to match the average amount carried out by middle-aged people in the UK. They will then undertake 3-months of reconditioning training to restore their fitness. In addition, twenty sedentary participants will increase their physical activity to UK recommended levels for six months. Before and at points during the intervention period, participants will be asked to make some measurements at home and attend the University of Nottingham to have multiple assessments made. These include; - fitness, muscle strength and function tests, - completion of questionnaires and computer-based brain puzzles - having muscle and fat tissue biopsies and blood samples taken. - The study also involves having MRI scans. This 5-year study will commence in January 2024, with participant recruitment starting in March 2024 and finishing in May 2027.

Description:

This is a parallel design study comparing the impact of physical activity and inactivity on the way the body functions, to understand the mechanisms (including the inter-relationship between tissues and organs) by which lifestyle behaviours may effect health and wellbeing in later life. In particular, the mechanisms by which inactivity results in long term poor health is not well understood, and has rarely been studied in an integrated way in people. However, initial research indicates that the physiology of being inactive is not simply the reverse of being active. To enable effective treatments and public health advice to be devised so that more adults reach old age in better health, and maintain a good quality of life for a greater proportion of their older age, it is important that the impact of physical inactivity on the way the body functions is better understood. Therefore, twenty participants who are moderately, but not highly active will be asked to decrease their physical activity for six months to match the average exercise levels of middle-aged people in the United Kingdom (UK). This will require them to increase their daily sitting time to 7 hours a day and reduce their step count to <4500 steps per day. At the end of the 6-months they will undertake 3-months of supervised reconditioning training to restore their fitness. In addition, twenty participants who currently have low physical activity levels will be asked to increase their physical activity to UK recommended levels by attending the Medical School at Queen's Medical Centre, Nottingham, three times a week for six months to undertake a supervised exercise program. Before and during the 6-month period (at weeks 6, 12, 18 and 24) participants will be asked to make some measurements at home (physical activity levels, dietary intake) and attend the University of Nottingham over 4 days to have multiple assessments made. These include: height; weight; body composition (body fat and lean tissue); blood pressure; fitness, muscle strength and function; sleep quality, quality of life and wellbeing (questionnaires). The rate of muscle protein breakdown and muscle protein synthesis, blood sugar regulation, and biochemistry of the blood, fat tissue and muscles will be assessed, and to enable this muscle and fat tissue biopsies will be collected and blood samples taken. The study also involves having MRI scans to study the structure and function of the brain and heart, and to determine liver and muscle fat content.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: October 31, 2028
• Est. primary completion date: December 17, 2027
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 55 Years to 65 Years

Eligibility

Inclusion Criteria:

• Group 1 ('non-sedentary') self-reporting <6 sedentary hrs/day, not actively involved in exercise training or a regular physical activity regimen (>8,000<10,000 steps/day).
• Group 2 ('sedentary') self-reporting =8 waking hrs/day in sedentary activities and/or =5,000 steps/day.
• Aged 55-65y.
• Overweight (BMI 25-29.9 kg/m2).
• Waist circumference =94cm (males) and =80cm (females).
• Willing to alter physical activity levels as instructed for 6 months
• Without neurological or psychiatric diseases, motor or cognitive restrictions
• Ability to give informed consent

Exclusion Criteria:

• Regular medication use that could interfere with measures
• A history, or evidence, of chronic cardiovascular, metabolic, musculoskeletal, renal or respiratory diseases.
• Experiencing 'long-COVID', inflammatory bowel disease or malignancy.
• Uncontrolled hypertension. Stage 1 hypertension (BP =160/100mmHg) with no other signs of cardiovascular disease, and blood pressure (BP) managed by routine medication will not be an exclusion.
• People employed in jobs that would preclude reducing step count and night-shift workers.
• Females who are pre/peri-menopausal or on hormone replacement therapy (due to effect of oestrogen fluctuations on primary outcomes and the longitudinal study design).
• Contraindications for MRI.
• Allergy or sensitivity to local anaesthesia, or dressing adhesive

Related Conditions & MeSH terms

• Age-related Cognitive Decline
• Age-Related Sarcopenia
• Cognitive Dysfunction
• Metabolic Syndrome
• Sarcopenia
• Sedentary Behavior

Intervention

Behavioral:
• Decreased Physical Activity
Physical activity levels will be decreased
• Increased Physical activity
Physical activity levels will be increased

Locations

Country	Name	City	State
United Kingdom	David Greenfield Human Physiology Unit	Nottingham	Notts

Sponsors (2)

Lead Sponsor	Collaborator
University of Nottingham	Biotechnology and Biological Sciences Research Council

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Fasting blood lipid concentration	concentration of lipid within the blood	pre-intervention
Other	Fasting blood lipid concentration	concentration of lipid within the blood	6 weeks
Other	Fasting blood lipid concentration	concentration of lipid within the blood	12 weeks
Other	Fasting blood lipid concentration	concentration of lipid within the blood	18 weeks
Other	Fasting blood lipid concentration	concentration of lipid within the blood	24 weeks
Other	liver function test: alanine transaminase (ALT)	concentration of ALT measured on blood sample	pre-intervention
Other	liver function test: alanine transaminase (ALT)	concentration of ALT measured on blood sample	6 weeks
Other	liver function test: alanine transaminase (ALT)	concentration of ALT measured on blood sample	12 weeks
Other	liver function test: alanine transaminase (ALT)	concentration of ALT measured on blood sample	18 weeks
Other	liver function test: alanine transaminase (ALT)	concentration of ALT measured on blood sample	24 weeks
Other	liver function test: aspartate aminotransferase (AST)	concentration of AST measured on blood sample	pre-intervention
Other	liver function test: aspartate aminotransferase (AST)	concentration of AST measured on blood sample	6 weeks
Other	liver function test: aspartate aminotransferase (AST)	concentration of AST measured on blood sample	12 weeks
Other	liver function test: aspartate aminotransferase (AST)	concentration of AST measured on blood sample	18 weeks
Other	liver function test: aspartate aminotransferase (AST)	concentration of AST measured on blood sample	24 weeks
Other	liver function test: Bilirubin	concentration of bilirubin measured on blood sample	pre-intervention
Other	liver function test: Bilirubin	concentration of bilirubin measured on blood sample	6 weeks
Other	liver function test: Bilirubin	concentration of bilirubin measured on blood sample	12 weeks
Other	liver function test: Bilirubin	concentration of bilirubin measured on blood sample	18 weeks
Other	liver function test: Bilirubin	concentration of bilirubin measured on blood sample	24 weeks
Other	liver function test: Albumin	concentration of albumin measured on blood sample	pre-intervention
Other	liver function test: Albumin	concentration of albumin measured on blood sample	6 weeks
Other	liver function test: Albumin	concentration of albumin measured on blood sample	12 weeks
Other	liver function test: Albumin	concentration of albumin measured on blood sample	18 weeks
Other	liver function test: Albumin	concentration of albumin measured on blood sample	24 weeks
Other	liver function test: Gamma glutamyl transferase (GGT)	concentration of GGT measured on blood sample	pre-intervention
Other	liver function test: Gamma glutamyl transferase (GGT)	concentration of GGT measured on blood sample	6 weeks
Other	liver function test: Gamma glutamyl transferase (GGT)	concentration of GGT measured on blood sample	12 weeks
Other	liver function test: Gamma glutamyl transferase (GGT)	concentration of GGT measured on blood sample	18 weeks
Other	liver function test: Gamma glutamyl transferase (GGT)	concentration of GGT measured on blood sample	24 weeks
Other	Blood Haemoglobin concentration	haemoglobin concentration measured on a blood sample	pre intervention
Other	Blood Haemoglobin concentration	haemoglobin concentration measured on a blood sample	6 weeks
Other	Blood Haemoglobin concentration	haemoglobin concentration measured on a blood sample	12 weeks
Other	Blood Haemoglobin concentration	haemoglobin concentration measured on a blood sample	18 weeks
Other	Blood Haemoglobin concentration	haemoglobin concentration measured on a blood sample	24 weeks
Primary	Change in Cardiorespiratory fitness (VO2 max)	change in maximal oxygen uptake (continuous incremental bicycle ergometer exercise test with on-line gas analysis) measured every 6 weeks	24 weeks
Secondary	Change in Isometric leg strength	Change in Isometric leg strength measured every 6 weeks using CYBEX dynamometer	24 weeks
Secondary	Change in time to leg fatigue	Change in time taken to induce muscle fatigue measured every 6 weeks using isokinetic knee extensions on a CYBEX dynamometer	24 weeks
Secondary	Change in incremental area under the curve (iAUC) for blood glucose concentration	Change in 180 minute blood glucose concentration incremental area under the curve measured every 6 weeks during an oral glucose tolerance test.	24 weeks
Secondary	Change in iAUC for serum insulin concentration	Change in 180-minute serum insulin concentration incremental area under the curve measured every 6 weeks during an oral glucose tolerance test	24 weeks
Secondary	Change in fasting glucose oxidation rate	Change in glucose oxidation rate (when fasted), measured every 6 weeks using ventilated hood indirect calorimetry	24 weeks
Secondary	Change in 'fed' glucose oxidation rate	Change in glucose oxidation rate (in the insulin-stimulated 'fed' state), measured every 6 weeks using ventilated hood indirect calorimetry during an oral glucose tolerance test	24 weeks
Secondary	Change in Short Form Health Survey (SF36) Questionnaire aggregated normalised 'physical' score	Change in 'SF36' Questionnaire aggregated 'physical' score (normalised to UK population) calculated according to standard procedures (min 0, max 100), with higher score indicating better physical wellbeing measured every 6 weeks	24 weeks
Secondary	Change in Short Form Health Survey (SF36) Questionnaire aggregated and normalised 'mental' score	Change in 'SF36' Questionnaire aggregated 'mental' score (normalised to UK population) calculated according to standard procedures (min 0, max 100), with higher score indicating better mental wellbeing, measured every 6 weeks	24 weeks
Secondary	Change in World Health Organisation Quality of Life (WHOQoL) score	Change in World Health Organisation Quality of Life Score (measured using the WHOQoL-Bref questionnaire every 6 weeks), (min score 0, max 100), with higher score indicating a better state of health.	24 weeks
Secondary	Change in Pittsburgh Sleep Quality Index (PSQI)	Change in PSQI score (min score 0, max 21), measured every 6 weeks, with higher score indicating poorer sleep quality	24 weeks
Secondary	Change in Stroop test; % Accuracy	Change in the percentage of accurate responses, measured every 6 weeks, with higher score indicating better cognitive performance. Minimum value 0%, maximum value 100%	24 weeks
Secondary	Change in Stroop test; reaction time	Change in the reaction time for responses, measured every 6 weeks, with higher score indicating slower cognitive performance. No minimum or maximum value defined.	24 weeks
Secondary	Change in four-choice reaction time test; % Accuracy	Change in the percentage of accurate responses, measured every 6 weeks, with higher score indicating better cognitive performance. Minimum value 0%, maximum value 100%	24 weeks
Secondary	Change in four-choice reaction time test; reaction time	Change in the reaction time for responses, measured every 6 weeks, with higher score indicating slower cognitive performance. No minimum or maximum value defined.	24 weeks
Secondary	Change in card sort test; % Accuracy	Change in the percentage of accurate responses, measured every 6 weeks, with higher score indicating better cognitive performance. Minimum value 0%, maximum value 100%	24 weeks
Secondary	Change in card sort test; reaction time	Change in the reaction time for responses, measured every 6 weeks, with higher score indicating slower cognitive performance. No minimum or maximum value defined.	24 weeks
Secondary	Change in Logical reasoning test; % accuracy	Change in the accuracy of responses, measured every 6 weeks, with higher score indicating better cognitive performance. Minimum value 0%, maximum value 100%	24 weeks
Secondary	Change in Logical reasoning test; reaction time	Change in the reaction time for responses, measured every 6 weeks, with higher score indicating slower cognitive performance. No minimum or maximum value defined.	24 weeks
Secondary	Change in serial subtractions test; number of responses in 2 minutes	Change in the number of responses, measured every 6 weeks, with higher score indicating better cognitive performance. minimum number is 0, maximum number is variable dependent on starting value (800-999; randomly selected by computer program) and speed of response.	24 weeks
Secondary	Change in Corsi blocks test; score	Change in the test score, measured every 6 weeks, with higher score indicating better cognitive performance.Minimum score is 0 and maximum is 15.	24 weeks
Secondary	Change in Muscle protein synthesis rate	Muscle synthesis protein rate calculated from deuterium incorporation into muscle tissue	24 weeks
Secondary	Change in Muscle protein breakdown rate	Muscle protein breakdown rate calculated every 6 weeks using 3-methylhistidine tracer	24 weeks
Secondary	Change in whole body fat volumes	Change in the amount of fat within the body, measured every 6 weeks using magnetic resonance imaging (MRI)	24 weeks
Secondary	Change in liver fat volumes	Change in the amount of fat within the liver, measured every 6 weeks using magnetic resonance imaging (MRI)	24 weeks
Secondary	Change in thigh muscle fat volumes	Change in the amount of fat within the vastus lateralis thigh muscle, measured every 6 weeks using magnetic resonance imaging (MRI)	24 weeks
Secondary	Change in whole body muscle volumes	Change in the amount of muscle within the body, measured every 6 weeks using magnetic resonance imaging (MRI)	24 weeks
Secondary	Change in muscle phosphocreatine synthesis rate	Change in the rate of phosphocreatine synthesis, measured every 6 weeks using magnetic resonance spectroscopy	24 weeks
Secondary	Change in cerebral volume	Change in the volume of brain tissue, measured every 6 weeks using magnetic resonance imaging (MRI)	24 weeks
Secondary	Change in cortical thickness	Change in the thickness of the brain cortex, measured every 6 weeks using magnetic resonance imaging (MRI)	24 weeks
Secondary	Change in plasma metabolome	change in untargeted plasma metabolome profile measured every 6 weeks	24 weeks